Jerod Denton

Grant aids drug discovery for autism, schizophrenia

Federal grant to help Vanderbilt researchers will pave the way for potential treatments for schizophrenia and autism spectrum disorder

Vanderbilt, Ono Pharmaceutical extend drug discovery agreement

Vanderbilt University Medical Center (VUMC), Vanderbilt University and Japan-based Ono Pharmaceutical Co. Ltd. have expanded a drug discovery agreement initiated in 2015 that will now run through 2019.

Emerging Scholar

Rene Raphemot, Ph.D., a National Institutes of Health postdoctoral fellow at Duke University, delivered the inaugural Discovery Science Emerging Scholars Lecture at Vanderbilt University School of Medicine last week.

Investigators explore new way to control mosquitoes

In a new study, Vanderbilt pharmacologist Jerod Denton, Ph.D., Ohio State entomologist Peter Piermarini, Ph.D., and colleagues report an experimental molecule that inhibits kidney function in mosquitoes and thus might provide a new way to control the deadliest animal on Earth.

Vanderbilt, Ono Pharmaceutical sign drug discovery agreement

Vanderbilt University Medical Center and Ono Pharmaceutical Group, an international company based in Japan, have signed a drug discovery agreement.

Channel drug restores glucose balance

A new compound that activates potassium channels could be used to treat disorders of glucose homeostasis.